Amgen will join leaders in the hematology community at the American Society of Hematology (ASH) Annual Meeting 2023, the premier meeting of hematologists, taking place in San Diego, December 8-10. In demonstration of Amgen's unwavering commitment to innovation, data being presented highlights the potential of the company's cutting-edge medicines in treating hematologic malignancies.
As a leader at the forefront of T-cell engager technology, Amgen's scientists have pioneered a series of 'firsts,' driving advancements in immuno-oncology with our Bispecific T-cell Engager (BiTE®) platform – a testament to ongoing research, which aims to address hematologic malignancies and challenging disease across therapeutic areas.
At ASH23, Amgen will highlight investigational data that support BiTE® immunotherapy into earlier lines of therapy for acute lymphoblastic lymphoma (ALL) and an important treatment option for multiple myeloma. Amgen will also share data in paroxysmal nocturnal hemoglobinuria (PNH) from the company's expanding biosimilar portfolio of medicines, which have the potential to increase patient access to lower-cost innovative therapies, providing patients with additional treatment options.
To learn more about Amgen's presence at ASH, view the press release here.
Be sure to follow Amgen Oncology on X (formerly known as Twitter) and LinkedIn for real-time updates throughout ASH.